The stock of Elanco Animal Health Incorporated (NYSE:ELAN) decreased by -$0.23 on Tuesday to finish at $11.77, down -1.92 percent. The last five days have seen an average of 4,384,780 shares of common stock traded. 10 times new highs were reached in the current year, with a fall of -$0.45. The average number of shares traded over the last 20 days was 6,567,330, while the average volume over the last 50 days totaled 6,332,722.
ELAN stock appreciated 2.17% since last month. On 07/17/23, the company’s shares reached a one-month low of $11.43. The stock touched a high of $20.02 on 02/02/23, after rallying from a low of $7.88 in 52 weeks. The price of ELAN stock has declined by -3.68% or -$0.45 this year, reaching a new high 10 times. Still, the stock price is down -41.21% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
ELAN stock investors should be aware that Elanco Animal Health Incorporated (ELAN) stock had its last reported insider trading activity 155 days ago on Mar 14. On Mar 14, Director HOOVER R DAVID acquired 5,000 shares at $9.55 each. This transaction resulted in the insider spending $47,750. On Mar 13, HOOVER R DAVID added 5,000 shares at a price of US$9.46. After the transaction, the insider now owns 160,000 shares. PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N had earlier bought 15,000 shares on Mar 10 for $9.60 a share. The transaction was completed for $143,972.
Valuation Metrics
Beta for the stock is 1.01. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 1.35, the price-to-book (PB) ratio of 0.78.
Financial Health
For the three months ended June 29, Elanco Animal Health Incorporated’s quick ratio was 1.50, while its current ratio was 2.80, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 0.81, and the total debt to equity ratio is 0.82. As far as profitability goes, gross margin for the trailing twelve months is 57.30% percent. Elanco Animal Health Incorporated’s EBITDA margin for the year ended June 29 was 24.17%, whereas its operating margin stood at 5.10% for the same period. Based on annual data, it had gross profit of $2.5 billion and revenue of $4.41 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. ELAN’s return on assets (ROA) during the last 12 months has been -0.60%. There was a 1.50% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -1.40%.
Earnings Surprise
According to Elanco Animal Health Incorporated’s quarterly financial report for the quarter that ended June 29. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $1.06 billion, while revenues fell by -11.35% to $1.26 billion. It was predicted that Elanco Animal Health Incorporated’s quarterly earnings would be $0.18, but it ended up being $0.05. EBITDA was $195.0 million for the quarter. At the end of Elanco Animal Health Incorporated’s most recent quarter ended June 29, its liabilities totaled 8.38 billion, while its total debt was $6.06 billion. Equity owned by shareholders amounts to $492.68 million.
Technical Picture
Here’s a quick look at Elanco Animal Health Incorporated’s (ELAN) price momentum from a technical perspective. As of 15 August, the RSI 9-day stood at 46.43%, suggesting the stock is Neutral, with a 29.93% historical volatility rate.
The stochastic %K and %D were 40.24% and 50.89% respectively, while the average true range (ATR) was 0.40. Based on the 14-day stochastic reading of 23.17%, the RSI (14) reading is 53.11%. On the 9-day MACD Oscillator, the stock is at -0.06, and the 14-day reading is at -0.04.
Analyst Ratings
In its most recent analyst report, Barclays raised its rating on Elanco Animal Health Incorporated (NYSE: ELAN) to an Overweight. Prior to this, analysts firm rated the stock as an Equal weight. Analysts have assigned Elanco Animal Health Incorporated (ELAN) an Hold rating. ELAN is a stock that is recommended for selling by 1 brokerage firm, while 5 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 1 rate it overweight and 3 others recommend it as a buy.
What is ELAN’s price target for the next 12 months?
The current consensus forecast for the stock is between $9.50 and $19.00, with a median target price of $13.50. In analyzing these forecasts, the average price target given by analysts for Elanco Animal Health Incorporated (ELAN) is $13.94.
